Human Milk-Derived L. reuteri FN041 Ameliorates Colitis via Microbiota and Metabolite Remodeling

Study Background and Research Question

Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by persistent inflammation of the colon and rectum, affecting over 5 million individuals globally. Despite advancements in UC therapies, many patients experience incomplete remission or disease recurrence, with more than 10% ultimately requiring surgical intervention. The gut microbiota’s role in intestinal homeostasis has become increasingly evident, as dysbiosis—marked by reduced diversity and a loss of beneficial species—contributes to UC pathogenesis through immune dysregulation and impaired barrier function. While several probiotics have shown benefit in clinical and preclinical UC studies, the therapeutic potential of strains isolated from human breast milk, such as Limosilactobacillus reuteri FN041, remains underexplored. The central question addressed in the reference study is whether L. reuteri FN041 can prevent or treat colitis via modulation of the gut microbiome and associated metabolite profiles.

Key Innovation from the Reference Study

This work is the first to systematically evaluate a human milk-derived L. reuteri strain (FN041) in a dextran sodium sulfate (DSS)-induced mouse model of colitis. The innovation lies in integrating high-resolution metagenomic and metabolomic analyses with immunological and histopathological assessments, providing a systems-level view of how a single probiotic strain may restore colonic health. Notably, the study moves beyond symptom alleviation to mechanistically link microbial community shifts and metabolite restoration with improved intestinal barrier function and reduced inflammation.

Methods and Experimental Design Insights

The researchers induced acute colitis in mice using DSS administered in drinking water, a widely accepted model that recapitulates key aspects of human UC. Mice were randomized to receive L. reuteri FN041 orally, with control groups including DSS-only and healthy untreated animals. Disease progression was monitored via weight loss, colon length, and clinical scoring (Disease Activity Index, Histological Index). Molecular endpoints included:

• Quantification of pro- and anti-inflammatory cytokines (IL-6, IL-10) in serum and colon tissue
• Assessment of oxidative stress markers (malondialdehyde)
• Measurement of serum lipopolysaccharide (LPS) and D-lactate as indicators of barrier permeability
• Expression analysis of tight junction proteins (e.g., occludin, claudin-1)
• Comprehensive fecal metagenomic sequencing to profile bacterial taxa
• Untargeted metabolomics of cecal contents to identify key metabolic changes

The integration of multi-omics data allowed for correlation analyses between clinical, microbiological, and metabolic parameters.

Protocol Parameters

• DSS-induced colitis: 2–5% DSS in drinking water for 5–7 days to induce acute colitis in mice.
• L. reuteri FN041 administration: Daily oral gavage at doses reflecting typical probiotic supplementation; precise colony-forming units (CFU) per dose detailed in the study.
• Sample collection: Fecal, serum, colon tissue, and cecal content collected at endpoint for multi-omics and histopathology.
• Protein quantification: Tissue or cell lysates analyzed for cytokine levels and tight junction proteins; protein assay selection (e.g., BCA) guided by compatibility with downstream immunoassays.

Core Findings and Why They Matter

L. reuteri FN041 administration led to a significant reduction in colitis severity, evidenced by decreased weight loss, prevention of colon shortening, and lower disease activity and histological scores. The probiotic treatment:

• Reduced both local (colonic) and systemic IL-6, while increasing anti-inflammatory IL-10 levels
• Lowered oxidative stress (malondialdehyde) and improved markers of epithelial barrier integrity (reduced LPS and D-lactate; increased tight junction protein expression)
• Remodeled the gut microbiota, increasing the relative abundance of beneficial commensals and suppressing taxa associated with inflammation and tissue damage
• Partially restored key metabolic markers (e.g., 1-myristoyl-sn-glycero-3-phosphocholine, gamma-L-glutamylputrescine, fosfomycin) that were disrupted by DSS
• Demonstrated that clinical improvement correlated with both microbiota composition and metabolite normalization

These results support a model in which L. reuteri FN041 acts not only through direct immunomodulation but also via ecosystem-level effects on the intestinal milieu, reinforcing the therapeutic rationale for targeted, next-generation probiotics in UC.

Comparison with Existing Internal Articles

While the reference study focuses on gastrointestinal disease and host-microbe interactions, related internal articles such as "Decoding Protein Quantification Fidelity: BCA Protein Assay Kit in Neurovascular Research" and "Precision Protein Quantification Beyond Neurobiology" emphasize the importance of accurate protein quantification in other domains, including neurovascular and respiratory research. These articles highlight the BCA Protein Assay Kit as a reliable and sensitive tool for measuring protein concentration in complex biological samples, which is equally relevant for quantifying cytokines and tight junction proteins in gastrointestinal disease models. The cross-talk between systemic inflammation, barrier integrity, and protein markers underscores the value of robust protein quantification workflows in both gastrointestinal and neurovascular research contexts.

Limitations and Transferability

Despite the comprehensive systems-level approach, several limitations warrant consideration. The model system (acute DSS-induced colitis in mice) may not capture all features of human UC, particularly chronic or relapsing disease. Only one probiotic strain was evaluated, and dose optimization or synergistic combinations with other microbiota-targeted therapies remain unexplored. Furthermore, while multi-omics correlation supports causality, definitive mechanistic links between specific microbes, metabolites, and host responses require additional validation (e.g., gnotobiotic or knockout models). Transferability to human patients will depend on further safety, efficacy, and mechanistic studies.

Research Support Resources

Reproducible quantification of key protein markers—including cytokines and junctional proteins—remains essential for validating immunological and barrier outcomes in colitis and related models. Researchers can streamline protein concentration measurement in tissue and cell lysates using the BCA Protein Assay Kit (SKU K4101), which offers high sensitivity and compatibility with diverse biological samples, as detailed in the internal workflow article. This assay supports accurate normalization for downstream analyses such as immunoblotting and ELISA, facilitating rigorous assessment of protein-level changes in experimental colitis and other models.